Archief Roodbont

October 7, 2008 — Proton-pump inhibitors (PPIs) should be the mainstay of treatment and prevention of gastrointestinal ulcers and bleeding in patients on antiplatelet therapy who are at increased risk for the gastrointestinal (GI) complications, according to an "expert consensus document" developed by the American College of Cardiology, American Heart Association, and American College of Gastroenterology and published online October 3, 2008 [1].